Molecular imaging developer Positron has completed its acquisition of Manhattan Isotope Technology (MIT).
Positron now owns MIT's assets and business operations and has retained all of the company's employees.
In exchange, MIT received cash advances, assumption of certain indebtedness, and earn-out consideration of $3.5 million, based on 20% of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.
